Al Reicheg

It’s time for pharma to rethink deployment models to meet evolving customer needs, as customer engagement preferences for both channel and frequency continue to change. My colleagues Scott Cohen and Megan Jackson take a closer look at declining access trends, address some of the top field deployment questions and offer tangible steps to evolve sales planning efforts. #oncology #pharma #futurecommercialmodel https://lnkd.in/eMEqApbn

12

This content is intended for U.S. audiences only. The countdown to Chicago is on, as we gear up for #ASCO24 in less than two weeks! For the first time, @AstraZeneca will headline not one, but TWO back-to-back plenary sessions in LUNG as well as a late-breaking study in BREAST. Our team is focused on treating cancers at earlier stages and across subtypes while advancing medicines and combination therapies that attack the disease from all angles, evidenced by our strong, diverse research to be presented in Chicago. Behind every data point is a patient, who deserves a personalised therapy that will give them a longer and healthier life. For each one, we’re pushing the boundaries of science, and I can’t wait to highlight our research advances in the coming weeks. Stay tuned! 🔬 For a more detailed preview of our #ASCO24 data presentations, please see our press release https://lnkd.in/ehH7tqFc #CancerResearch #oncology #MedicalAdvancements

224

3 Comments

Patients, healthcare professionals, payers, and other stakeholders can have vastly different views on the value of a particular product, often resulting in a struggle between prioritizing access to innovation and optimizing costs. Addressing the ramifications associated with misaligned incentives in the fee-for-service payment model has been a driving force in the pursuit of value-based care. Read more: https://ow.ly/YcV430sCN0A

36

Happy Monday, LinkedIn Colleagues and Connections! It's a short week ahead, but I've got something valuable for brand marketers deep in planning mode to consider. Did you know there are now more than 730,000 NPs and PAs in the United States! These two professions are among the fastest-growing, with their numbers increasing significantly over the last decade. Here's another interesting fact: NPs and PAs have NPI numbers, it's a requirement for billing when working with CMS. Let's connect and discuss how POCN Group can help you better understand the needs and challenges of these essential healthcare providers. #PharmaMarketing #Healthcare #NPs #PAs #POCNGroup

7

The 340B Drug Pricing Program has grown significantly in recent years. States have responded by passing additional legislation, creating a complex policy landscape that’s challenging for both manufacturers and providers. My colleagues explore pharma’s and states’ policy responses, analyze how successful these responses have been and offer recommendations for how pharma can adapt in a dynamic environment.  #healthcare #pharma #340B #drugpricing #publicpolicy https://lnkd.in/eJwm-NrN

8

There are endless barriers for patients to initiate and adhere to their specialty medications, from cost to insurance approvals and beyond. In our recent #blog, we break down some of these barriers and discuss the ways in which innovative technologies can help patients and providers accelerate enrollment and achieve better outcomes. ⚡ Check it out! #specialtypharmacy #digitalhealth #medaccess

28

Thank you Outcomes Rocket for allowing me on this Podcast!!! Finding ways to get necessary medications into the hands of our loved ones faster is the heartbeat of RxLightning! Watch the rest of this podcast to learn more about what we do: https://lnkd.in/e_6FEtAk #podcast #specialty #medication #healthcare

41

🧓👵👴Long-Term Care Gets a Tech Boost: How New Advancements Benefit Seniors and Pharmacists? Here at TIB Pharmacy, we're passionate about empowering our patients to live healthy, independent lives. That's why I'm thrilled about the recent surge in technology designed to support seniors in long-term care facilities and even at home. As your pharmacist, I've seen firsthand how these advancements can benefit patients: **Improved Medication Adherence: Medication reminders and easy video calls with caregivers can significantly improve medication adherence, reducing complications and potentially lowering the need for additional prescriptions. **Early Detection of Health Concerns: Wearable health trackers can monitor vitals and activity levels, allowing for earlier detection of potential health issues. This means faster intervention and potentially fewer medication adjustments due to missed symptoms. **Promoting Independence: Technology like GPS trackers and video calls empowers seniors to manage their daily lives at home, reducing feelings of isolation and potentially decreasing the need for certain medications used to manage those conditions. Here's how I can help: **Educating Patients and Families: I'm happy to discuss these advancements with you and your loved ones, exploring how they can improve well-being and potentially reduce medication-related issues. **Partnering with LTC Facilities: Collaboration with LTC facilities ensures residents receive the medications they need while seamlessly integrating these new technologies. **Staying Current on the Latest Tech: The world of senior care technology is constantly evolving. I'm committed to staying up-to-date to best serve my patients. Technology is transforming long-term care, and at TIB Pharmacy, we're excited to be part of it. Let's work together to create a future where seniors can enjoy a higher quality of life with greater independence and better health outcomes. Let us know your thoughts about this, feel free to share it in the comments section! Call us! TIB Pharmacy T: (510)-573-0064 A: 5886 Mowry School Rd, Newark CA, 94560 #LongTermCare #MedicationManagement #BetterHealth #Teamwork #TIBPharmacy #NewarkPharmacy #pharmacyservices #longtermcare #LTCPharmacy #HospicePharmacy #EndOfLifeCare #hospicespecialized #ltcspecialized #ltcathome #enteraltherapy #MedicationManagement #PackagingPower #SimplifyYourHealth https://lnkd.in/gUWj3PGp

3

1 Comment

“This is how it has always been done” or “This is how everyone does it” are no longer sufficient. We have to be creative and take risks to disrupt the status quo and forge new paths. #healthcare #clinicaltrials #raredisease

13

2 Comments

Totally agree with Josh Bernoff here about naming your book. Catchy (title) plus briefly explanatory (subtitle) is the way to go. https://lnkd.in/gbxU7e7r Grab attention and memory. Then address understanding. Make both intriguing.

2

2 Comments

As groundbreaking treatments and novel therapies are continuously being approved, there are a multitude of challenges encountered by industry stakeholders. Don't miss the recent issue of Healthcare Tech Outlook to discover how AscellaHealth’s proactive approach drives commercialization success for clients and enhances outcomes for patients. Read more here: https://lnkd.in/eG9NHSrM #AscellaHealth #lifesciences #technology #specialtypharmacy

19

1 Comment

Annual reverification doesn’t need to be a “blizzard.” Read more in our Patient Solutions Division President Jan Nielsen’s Drug Channels Institute, an HMP Global company, article on what life sciences organizations can do to shift their strategy from reactive spikes to proactive tech-first solutions.    #InformedAccess #ImprovedOutcomes  

31

In a new report focusing on portfolio strategy and business development, my colleagues Cody Powers and Josh Hattem share data around #pharma launches and approvals, what’s driving industry growth, why clinical trials continue to decline and more.  https://lnkd.in/edghcwTS

21

To discuss how to de-risk your viral vector prior to clinical trials, please reach out to our team at #ISCT2024 in Vancouver. Farzin Farzaneh, PhD Traci Kyes Makis Sigalas

23

As payers seek to take back control of their pharmacy and medical spend, Site of Care (SOC) optimization is an opportunity to capture savings. Check out AscellaHealth's recent Payer Spotlight to learn more: https://lnkd.in/e6XPzvhi #payersolutions #managingcosts #specialtytherapies #specialtypharmacy #HealthcarePayers #healthplans

11

Many states now scrutinizing healthcare consolidation Thirty-five states currently have laws that require not-for-profit healthcare entities that meet certain requirements, usually based on revenue size, to report M&A activity to state regulators. Fourteen of these states extend these requirements to for-profit healthcare entities as well. Although some believe that these state laws will help preserve healthcare competition and access, they will increase the complexity, cost, and timeline for healthcare entities seeking to merge and could make survival for smaller providers even more difficult.

3

Departing Words: Merck’s Ken Frazier Cautions Against Profit Maximization Pharma CEOs must balance optimizing access and profitability, former Merck CEO and soon-to-be ex executive chairman of the company said. Frazier says health care industry must come to table and admit the “system ain’t working,” talks about the need to protect democracy, in a sweeping interview at the STAT Summit. ....from the Citeline archives, via Sarah Karlin-Smith ********** In a court filing reported yesterday by Bloomberg Law reporter Celine Castronuovo, Amgen argues it will suffer “concrete harm” unless a federal judge quickly enjoins Colorado’s drug pricing board from moving forward with a payment cap for Enbrel. Like nearly all content in healthcare today, Amgen's storyline starts and sticks with the Standard Model, the cut-and-paste messaging that now sits at the extreme end of monotonous repetition. To wit: "Innovative medicines have enhanced and extended the lives of countless Coloradans. Recognizing the enormous investment of time and money needed to discover and develop these novel treatments, Congress rewarded those who bring new medicines to market with a period of patent exclusivity and pricing discretion. As numerous scholars have observed, the economic incentives provided by the federal patent system are crucial to Congress’s objective of promoting pharmaceutical research and development. One such medicine, Amgen’s pioneering drug ENBREL® provides life-changing relief to thousands of Coloradans who suffer from arthritis and other autoimmune diseases. Enbrel redefined the clinical course of moderate to severe rheumatoid arthritis...." etc., etc., etc., etc. All of which may be technically true, as "the scholars have observed", but if the objective for Amgen is an argument that persuades, the #StandardModel stopped working long ago. It also doesn't help when the 20 members of the Colorado drug pricing board and its advisory council come home from work and watch the local news, where the commercial breaks will be flooded with drug promotion, part of the media buy that comes from the industry spending $30 billion/year on DTC advertising. These things are connected. In a conversation with Bill Boulding, Dean of Duke University - The Fuqua School of Business around the same time as his interview with STAT, Frazier said one of the role's of business was in collaborating with government to reinvent the country. “The role of the private sector in the United States in helping to reinvent this country, over, and over, and over again, is important,” he said. “I think business has the talent, it has the resources, it has the capabilities of helping to change our country.” It's time to sweep the old concepts out of the saddle. The faster the drug market learns how to connect things differently, to 'see, say, sell and sustain' strategy at a system level, the faster it can start creating a different future for itself. #QuentinTarantino

10

1 Comment

Every day a new story emerges about AI. But I’m really interested to see how we can make AI work for clinical trials. Could it even shorten time to market? To map its trajectory, we must look to its past. This Medidata Solutions article tells the story of AI in healthcare so far. And for anyone in life sciences, there’s a thought-provoking section on the value and challenges that come with bringing in AI and ML to the clinical research field. I’d love to hear what you think. Are you for or against AI in clinical trials? https://rebrand.ly/p90dwmd #Medidata #AI #MachineLearning #ClinicalTrials

19